All In Biotech

Drug Trial Radar · NCT06520540

HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Oral Administration of HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

72

Planned (sponsor's estimate)

Start

Jul 28, 2024

Primary completion

Nov 30, 2024

Study completion Dec 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

• To assess the safety of multiple oral doses of HDM1002 tablets under different titrations in Chinese overweight and obese adult subjects.

Conditions

  • Glucagon-Like Peptide-1 Receptor Agonists

Interventions

  • HDM1002 100 mg QD 12weeksDrug

    Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)

  • HDM1002 200 mg QD 12weeksDrug

    Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)

  • HDM1002 400 mg QD 12weeks,Q 2W for titrationDrug

    Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

  • HDM1002 400 mg QD 12weeks,Q 3W for titrationDrug

    Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

  • PlaceboDevice

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. TEAEs, SAEs, AEs leading to withdrawal, and AEs leading to death, AEs of special interestTime frame: Baseline, Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HDM1002

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.